Conformal Medical Closes $32 Million Series D Extension to Advance its Next-Generation Left Atrial Appendage Occlusion Technology
NASHUA, N.H., Aug. 12, 2025 /PRNewswire/ — Conformal Medical, Inc., a medical device company developing next-generation left atrial appendage occlusion (LAAO) technology, announced the successful closing of its Series D extension financing, with a new partner joining inside investors to raise a total of $32 million.
The funds will support the enrollment of the company's ongoing CONFORM Pivotal Trial and fund key pre-commercialization initiatives for CLAAS® AcuFORM™ LAAO system. The CONFORM Pivotal Trial is the company's clinical trial evaluating the safety and efficacy of the CLAAS® System compared to other commercially available LAAO devices and will support U.S. Food and Drug Administration (FDA) pre-market approval. The CLAAS AcuFORM System is designed to seal the left atrial appendage (LAA) in patients with non-valvular atrial fibrillation (AFib) to reduce the risk of stroke without the need for anticoagulants.
'We are pleased to have treated over 100 patients with the next-generation AcuFORM™ System, with impressive deliverability and safety performance to date,' said James Reinstein, President and CEO of Conformal Medical. 'We look forward to building upon this robust body of evidence to further validate our one-size strategy, and the promising experience from our GLACE trial, demonstrating successful use of ICE guidance as it would eliminate the need for general anesthesia and intubation for these procedures.'
Conformal Medical's proprietary CLAAS AcuFORM technology features a foam-based architecture designed to conform to a broad range of LAA anatomies with only two sizes. The AcuFORM device may also accelerate the shift to ICE-guided LAAO closure due to simplified sizing and seal confirmation, thereby potentially eliminating the need for a procedural transesophageal echocardiogram and general anesthesia. This is a significant advancement with the potential to shift clinical practice to a single-operator procedure that is less invasive for patients. The company remains focused on completing the CONFORM and GLACE clinical trials to demonstrate its safety profile and ability to offer breakthrough solutions that address unmet clinical needs and transform the way Left Atrial Appendage Occlusion is treated.
Piper Sandler acted as exclusive financial advisor, and Gunderson Dettmer acted as legal counsel to Conformal Medical in this transaction.
About CONFORM Pivotal Trial The CONFORM Pivotal Trial is a prospective, multicenter, randomized controlled study evaluating the safety and efficacy of the Conformal CLAAS AcuFORM System compared to other commercially available left atrial appendage (LAA) devices. The trial plans to randomize approximately 1,600 patients at sites worldwide and is now >30% enrolled. It aims to generate pivotal data supporting next-generation stroke prevention therapies for individuals with non-valvular atrial fibrillation (AFib) who are seeking an alternative to long-term oral anticoagulation. For more information, visit https://conformalmedical.com/patient/enroll-in-trial.
About Conformal Medical Conformal Medical, Inc. is a medical device company developing devices to prevent stroke in patients with non-valvular atrial fibrillation. The company's proprietary technology is intended to make left atrial appendage closure a same-day, single-operator procedure. For more information, visit https://conformalmedical.com/.
CAUTION: Investigational Device. The CLAAS System is limited by Federal (or United States) law to investigational use.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Malaysian Reserve
15 minutes ago
- Malaysian Reserve
Resolutions Adopted by the 2025 General Extraordinary Shareholders' Meeting
MEXICO CITY, Aug. 12, 2025 /PRNewswire/ — Grupo Rotoplas, S.A.B. de C.V. (BMV: AGUA*) ('Rotoplas' or 'The Company'), leader in water management solutions in the Americas, informs the investing public about the proposals approved at the Extraordinary General Shareholders' Meeting held today, August 12th, 2025, at 10:00 am in Mexico City. Capital reimbursement to the Company's shareholders through a reduction of share capital. A capital reimbursement in cash to the Company's shareholders through a capital reduction in the amount of $0.25 (twenty-five cents MXN) per each outstanding share was approved. The corresponding payment will be made in cash in a single installment through the S.D. Indeval Institución para el Depósito de Valores, S.A. de C.V., as of August 21st, 2025. Investor Relations Contacts Mariana Fernández mfernandez@ María Fernanda Escobar mfescobar@ agua@ About the Company Grupo Rotoplas S.A.B. de C.V. is America's leading provider of water solutions, including products and services for storing, piping, improving, treating, and recycling water. With over 45 years of experience in the industry and 18 plants throughout the Americas, Rotoplas is present in 14 countries and has a portfolio that includes 27 product lines, a services platform, and an e-commerce business. Grupo Rotoplas has been listed on the Mexican Stock Exchange (BMV) under the ticker 'AGUA' since December 10th, 2014. Pedregal 24, piso 19, Col. Molino del ReyMiguel HidalgoC.P. 11040, Ciudad de MéxicoT. +52 (55) 5201
Malaysian Reserve
20 minutes ago
- Malaysian Reserve
All U Need Pest Control Ranks No. 1148 on the 2025 Inc. 5000 List of Fastest-Growing Private Companies
FORT MYERS, Fla., Aug. 12, 2025 /PRNewswire/ — All U Need Pest Control has once again been recognized as one of the fastest-growing private companies in America, earning the No. 1148 spot on the prestigious 2025 Inc. 5000 list. This milestone marks the fourth consecutive year the company has been honored, underscoring its consistent growth, resilience, and commitment to exceptional service in the pest control industry. The Inc. 5000 list offers a data-driven snapshot of the country's most successful independent businesses—those driving innovation, creating jobs, and fueling the U.S. economy. Past honorees include household names like Microsoft, Meta, Chobani, Under Armour, Timberland, Oracle, and Patagonia. 'Making the Inc. 5000 list for the fourth straight year means a lot to us,' said Kyle Selbach, Director of Operations at All U Need Pest Control. 'It's proof that when you have a strong team and supportive customers, you can accomplish big things. We're proud to keep delivering safe, reliable pest control and to keep earning the trust of the communities we serve.' Since its founding, All U Need Pest Control has expanded from a single location to 12 offices across three states, serving thousands of customers with a full range of residential and commercial pest management solutions. The company has earned multiple awards for growth and customer satisfaction, including repeated recognition on both the Inc. 5000 and the PCT Top 100 Pest Control Companies list. This year's Inc. 5000 honorees have demonstrated exceptional growth despite economic uncertainty, inflation, and labor market shifts. Among the top 500 companies, the median three-year revenue growth rate reached 1,552 percent, with these companies collectively adding over 48,000 jobs to the U.S. economy in the past three years. For the complete 2025 Inc. 5000 list, visit About All U Need Pest Control All U Need Pest Control is a Florida-based, family-owned pest management company providing safe, reliable, and eco-friendly solutions for homes and businesses. With a focus on exceptional customer service and proven results, the company offers comprehensive pest control, termite prevention, mosquito management, and more—ensuring customers can enjoy their spaces pest-free, all year long. Media Contact: Tyler Moore Director of Marketing All U Need Pest Control (239) 236-4094 tyler@
Malaysian Reserve
an hour ago
- Malaysian Reserve
FRE Alcohol-Removed Wines Renews as Official Non-Alc Wine Partner of Create & Cultivate
From supper clubs to summits, FRE will continue to champion connection and inclusion as Create & Cultivate's exclusive non-alc wine partner. ST. HELENA, Calif., Aug. 12, 2025 /PRNewswire/ — After a powerful year of community, creativity, and connection, FRE Alcohol-Removed Wines is proud to announce the renewal of its partnership with Create & Cultivate, extending its role as the Official Non-Alcoholic Wine Partner into 2026. This renewed collaboration builds on the deep relationships and vibrant events developed throughout the past year, ranging from intimate Supper Clubs to the world's largest festival for women in business. FRE has consistently shown up for its community, pouring thoughtful, alcohol-removed options into the moments that matter most. Create & Cultivate is the leading events and media company for ambitious women in business, known for uniting a powerful network of entrepreneurs, creatives, and thought leaders. With a fan-favorite podcast, curated digital content, and highly anticipated events like the 7-Figure Founder Retreat and Future Summit, Create & Cultivate helps women connect, learn, and grow at every stage of their careers. 'As a brand, we're committed to being present wherever our audience is, offering elevated non-alc options at every stage of their journey,' said Ashley Jappe, Director of Marketing at FRE. 'Partnering with Create & Cultivate has been a perfect extension of that promise. Whether someone is launching a new business, switching careers, or simply reconnecting with what wellness means to them, we want to make sure there's something in their glass that matches the occasion.' Over the past year, FRE has helped toast new ventures, big ideas, and genuine connections across Create & Cultivate's signature events. The partnership has included intentional tasting experiences, all designed to meet ambitious women where they are, with a thoughtful pour in hand. 'As we move into another year of collaboration, our goal remains the same: to support and uplift the incredible women who power our community,' said Marina Middleton, CEO of Create & Cultivate. 'FRE understands the importance of inclusivity and connection, and their presence at our events helps ensure every guest feels seen, celebrated, and included.' In 2025, FRE will continue to be featured at all Create & Cultivate Supper Clubs across the country, host dinners at Create & Cultivate's 7-Figure Founder Retreats, and activate at the SXSW Future Summit in Austin. With every activation, the brand will show that meaningful connection can flourish through intentional, non-alcoholic moments. For more information about FRE Alcohol-Removed Wines visit or follow @FREWines on social media. About FRE Alcohol-Removed WinesFRE Wines caters to a diverse range of consumers including those who abstain from alcohol, the sober curious, health-conscious individuals, and those who appreciate both alcoholic and non-alcoholic options. FRE Wines undergo the full vinification process: the grapes are meticulously grown, harvested, and fermented, as in traditional wines. After fermentation, the alcohol is gently removed using advanced techniques, preserving the wine's complexity, mouthfeel and aroma, giving a true to wine experience. Offerings include FRE Chardonnay and Cabernet Sauvignon in mini 187ml bottles, and FRE Sparkling Brut, Moscato, Sauvignon Blanc, White Zinfandel, Rosé, Chardonnay, Pinot Grigio, Merlot, Red Blend, and Cabernet Sauvignon in standard 750mL bottles. About Create & CultivateCreate & Cultivate is the largest market-leading events and media company created for women in business to connect, learn, and grow. Through its innovative online platform, best-in-class curated events, and the fan-favorite Workparty podcast, Create & Cultivate fosters a vibrant ecosystem for women to explore, connect, and excel. Known for uniting industry leaders, entrepreneurs, and celebrities, the company offers a dynamic space where strategic insights and authentic connections drive professional and personal growth. For more information, visit or follow them on social media.
